Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KT-579 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| KT-579 | ACTIVE_COMPARATOR | Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of KT-579. |
| Placebo | PLACEBO_COMPARATOR | Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of matched placebo. |
| Name | Type | Description |
|---|---|---|
| KT-579 | DRUG | Oral drug |
| Placebo | DRUG | Oral drug |
Inclusion Criteria: * Participants with a weight of at least 50 kg if male or 40 kg if female, and a body mass index (BMI) between 18.0 and 32.0 kg/m² (inclusive) at Screening. * Participants must be willing and able to read, understand, and sign an informed consent form (ICF) which includes compli...
KT-579 is an investigational small molecule being developed by Kymera Therapeutics for use in healthy participants. It is currently in Phase 1 clinical development, with an ongoing first-in-human study evaluating its safety, tolerability, and pharmacokinetics after oral administration.
KT-579 targets IRF5, a transcription factor involved in immune regulation. By modulating IRF5 activity, the drug is being studied for its potential effects in healthy participants, though its specific therapeutic application has not been disclosed.
KT-579 is being developed by Kymera Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol KYMR. The company is conducting a Phase 1 clinical trial of KT-579 in healthy adult participants.
KT-579 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is currently being studied in a first-in-human trial to assess its safety and tolerability in healthy volunteers.
KT-579 is being evaluated in a Phase 1 clinical trial with the identifier NCT07412288, titled "First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants." This randomized, double-blind, placebo-controlled study is recruiting 96 participants in the United States.
No alternative names for KT-579 have been disclosed. It is a distinct investigational small molecule developed by Kymera Therapeutics, and no other drug names have been associated with it in available clinical trial information.